Lineage Cell Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-63.5M | $-18.6M | $-21.5M | $-26.3M | $-43.0M | $-20.6M | $-11.7M | $-46.0M |
| Depreciation & Amortization | $699.0K | $587.0K | $562.0K | $582.0K | $663.0K | $823.0K | $1.0M | $1.1M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $0 | $22.0K | $130.0K | $145.0K | $210.0K | $1.2M | $2.0M | $2.2M |
| Stock-Based Compensation | $4.8M | $5.1M | $4.6M | $4.3M | $3.5M | $2.2M | $3.6M | $5.4M |
| Net Cash from Operating Activities | $-18.9M | $-23.1M | $-28.6M | $1.1M | $-23.6M | $-19.8M | $-31.9M | $-30.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $522.0K | $565.0K | $674.0K | $413.0K | $340.0K | $64.0K | $440.0K | $556.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-13.5M | $-2.3M | $46.4M | $-46.2M | $9.7M | $13.0M | $17.0M | $11.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $27.0M | $35.9M | $6.4M | $1.6M | $36.9M | $29.9M | $617.0K | $5.8M |
| Net Change in Cash | $-5.0M | $10.4M | $24.1M | $-44.3M | $23.1M | $23.1M | $-14.3M | $-13.3M |
| Free Cash Flow | $-19.4M | $-23.7M | $-29.2M | $646.0K | $-23.9M | $-19.8M | $-32.4M | $-31.4M |